Queen’s University has teamed up with a medical imaging company in a venture that has the potential to revolutionise cancer detection and treatment.
The university’s spin-out company QUBIS has taken an equity shareholding in Cirdan Imaging, which develops imaging equipment to assist clinicians in the detection, diagnosis and treatment of cancer.
The new devices will be used in diagnostic procedures, as well as cancer surgery, to better discriminate between healthy and malignant tissue.
The company said it expects to float on the London stock market within the next five years, following in the footsteps of Andor Technology, which currently trades on the AIM market and was a product of a previous collaboration between QUBIS and Cirdan Imaging chief executive Dr Hugh Cormican.
“We know that speed of detection and treatment of cancer is critical to patient outcomes and we hope that through this new faster, more efficient technology, patient outcomes and survival will be improved,” he said.
“Queen's University is one of the world's leading research |centres for Cancer Research, and with our collaboration we can help bring the benefits of that |research to impact on patient's lives in considerably shorter timescales than occur elsewhere in the world,” said Dr Cormican.
Cirdan Imaging’s first new device will be an imaging tool developed to assist radiologists take a biopsy from a suspect lesion to help diagnose breast cancer.
The product is planned to be launched within the next 12 months.